OSUR earnings call for the period ending June 30, 2019.
News & Analysis: OraSure Technologies
Lower demand from a key customer has reduced the company's sales outlook.
Shares bounced back from their drubbing in November.
A large sale to a single customer has investors excited about the diagnostic company's prospects.
Shares plunged even though the company reported upbeat results. What gives?
A solid second quarter from the diagnostic test maker.
It looks like OraSure's HIV self-test will get a distribution boost with a little help from the Bill and Melinda Gates Foundation.
A deal with the Gates Foundation should boost revenue.
A solid start to 2017 for the diagnostic-test specialist.
It was an outstanding fourth quarter for the diagnostic test maker, and there's more to come this year.
Shares jump in response to two pieces of good news.